

Consolidated Financial Results for Fiscal 2016

(Reference Data of Financial Statements Fiscal 2016 1st Quarter)

August 3, 2016

KAKEN PHARMACEUTICAL CO., LTD.

Corporate Communications

Tel: +81-(0)3-5977-5002

Fax: +81-(0)3-5977-5131

Email: koho@kaken.co.jp

ACRUX DDS PTY LTD. et al.

EXHIBIT 1649

IPR Petition for

1. Summary of Consolidated Financial Statements for Fiscal 2016 1st Quarter

(Figures less than one million yen have been omitted)

	FY2015 1st Q	FY2015	FY2016 1st Q	Y o Y increase (decrease)		Plan FY2016	Y o Y increase (decrease)	
				Yen	%		Yen	%
Net sales	27,633	109,730	26,228	(1,405)	94.9%	106,100	(3,630)	96.7%
Operating income	9,234	35,146	8,097	(1,136)	87.7%	28,900	(6,246)	82.2%
Ratio of net sales	33.4%	32.0%	30.9%			27.2%		
Ordinary income	9,362	35,365	8,217	(1,145)	87.8%	29,100	(6,265)	82.3%
Ratio of net sales	33.9%	32.2%	31.3%			27.4%		
Net income	6,300	21,143	5,796	(503)	92.0%	20,800	(343)	98.4%
Ratio of net sales	22.8%	19.3%	22.1%			19.6%		
Comprehensive income	6,460	18,444	5,158	(1,301)	79.8%			
R&D expenses	1,408	5,883	1,899	490	134.8%	10,200	4,317	173.4%

2. Breakdown of Sales by Main Pharmaceuticals and Medical Devices

(Figures less than one million yen have been omitted)

	FY2015 1st Q	FY2015	FY2016 1st Q	%	Plan FY2016	%
Anti-osteoarthritis Artz	8,020	30,760	7,754	96.7%	29,300	95.3%
Anti-nail fungus Clenafin	4,499	19,868	5,796	128.8%	23,800	119.8%
Post-operative anti-adhesive Septrafilm	2,714	11,262	2,701	99.5%	11,500	102.1%
Anti-hyperlipidemia Lipidil	1,123	4,526	1,133	100.8%	4,300	95.0%
Wound healing agent Fiblast Spray	924	3,617	941	101.9%	3,700	102.3%
Generic products	3,330	13,292	3,045	91.4%	12,700	95.5%
Sales of Jublia*	1,717	5,722	1,033	60.2%	4,100	71.7%

(*including sales of API and finished product, royalty revenue, milestone revenue and initial payment)